Equity rights offering subscription deadline
Company: Core Scientific
What the later record shows
Delivered on time · happened January 5, 2024
The 10-Q states the ERO subscription period expired on January 5, 2024 and the offering was oversubscribed. The 424B3 says the rights offering was consummated on the Effective Date.
“the Company commenced an equity rights offering in accordance therewith on November 20, 2023, which was consummated on the Effective Date”
2024-05-05 · Core Scientific 424B3 filed 2024-05-06 View cached copy (2026-08-31)Live source ↗
“The subscription period for the ERO expired on January 5, 2024. The Equity Rights Offering was oversubscribed”
2024-11-05 · Core Scientific 10-Q filed 2024-11-06 View cached copy (2026-08-31)Live source ↗
Checked November 15, 2026 against filings, releases and reporting published after the claim was made. Quotes are verbatim from the linked documents.
The claim, verbatim
The equity rights offering subscription period ends, and subscription amounts must be funded, by January 5, 2024.
Source (primary)
core-scientific 8-K exhibit (d162706dex991.htm) (SEC EDGAR (8-K Ex), press_release)
View cached copy (2026-11-15)Live source ↗
Quote: “End of Rights Offering Subscription Period/ Deadline for Funding Rights Offering Subscription Amounts January 5, 2024”
How we checked this
Checked on November 16, 2026. The cited source supports every part of this claim.
The release's timeline table lists January 5, 2024 as both the end of the subscription period and the funding deadline, though the table is labeled illustrative.
Confirmed in the source:
- The equity rights offering subscription period ends January 5, 2024
- January 5, 2024 is the deadline for funding rights offering subscription amounts
What we did: Read our cached copy of SEC EDGAR (8-K Ex) (https://www.sec.gov/Archives/edgar/data/1839341/000119312524003423/d162706dex991.htm) in full (7,277 characters, retrieved November 15, 2026) and checked each assertion in the claim against it.
Additional evidence
confirms core-scientific 8-K exhibit (d162706dex991.htm)
Quote: “End of Rights Offering Subscription Period/ Deadline for Funding Rights Offering Subscription Amounts January 5, 2024”
confirms Core Scientific 424B3 filed 2024-05-06
Quote: “the Company commenced an equity rights offering in accordance therewith on November 20, 2023, which was consummated on the Effective Date”
confirms Core Scientific 10-Q filed 2024-11-06
Quote: “The subscription period for the ERO expired on January 5, 2024. The Equity Rights Offering was oversubscribed”